Way 100135 | CAS#133025-23-7 | 5-HT1A Receptor Antagonist

MedKoo Cat#: 526561 | Name: Way 100135

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Way 100135 is a serotonergic drug of the phenylpiperazine family which is used in scientific research. It acts as potent 5-HT1A receptor antagonist, and was originally believed to be highly selective, but further studies have demonstrated that it also acts as a partial agonist of the 5-HT1D receptor (pKi = 7.58; virtually the same affinity for 5-HT1A), and to a much lesser extent, of the 5-HT1B receptor (pKi = 5.82). These findings may have prompted the development of the related compound WAY-100,635, another purportedly selective and even more potent 5-HT1A antagonist, which was synthesized shortly thereafter.

Chemical Structure

Way 100135

CAS#133025-23-7 (free)

Theoretical Analysis

MedKoo Cat#: 526561

Name: Way 100135

CAS#: 133025-23-7 (free)

Chemical Formula: C24H33N3O2

Exact Mass: 395.2573

Molecular Weight: 395.55

Elemental Analysis: C, 72.88; H, 8.41; N, 10.62; O, 8.09

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 230.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

133025-23-7 (free) 149007-54-5 (hydrochloride)

Synonym

Way100135; Way-100135; Way 100135

IUPAC/Chemical Name

N-(tert-butyl)-3-(4-(2-methoxyphenyl)piperazin-1-yl)-2-phenylpropanamide

InChi Key

UMTDAKAAYOXIKU-UHFFFAOYSA-N

InChi Code

InChI=1S/C24H33N3O2/c1-24(2,3)25-23(28)20(19-10-6-5-7-11-19)18-26-14-16-27(17-15-26)21-12-8-9-13-22(21)29-4/h5-13,20H,14-18H2,1-4H3,(H,25,28)

SMILES Code

O=C(NC(C)(C)C)C(C1=CC=CC=C1)CN2CCN(C3=CC=CC=C3OC)CC2

Appearance

White to off-white solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 395.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kazmierska P, Konopacki J. Development of theta rhythm in hippocampal formation slices perfused with 5-HT1A antagonist, (S)WAY 100135. Brain Res. 2015 Nov 2;1625:142-50. doi: 10.1016/j.brainres.2015.08.041. Epub 2015 Sep 7. PubMed PMID: 26358147. 2: Wedzony K, Maćkowiak M, Zajaczkowski W, Fijał K, Chocyk A, Czyrak A. WAY 100135, an antagonist of 5-HT1A serotonin receptors, attenuates psychotomimetic effects of MK-801. Neuropsychopharmacology. 2000 Nov;23(5):547-59. PubMed PMID: 11027920. 3: Lopez-Mendoza D, Aguilar-Bravo H, Swanson HH. Combined effects of Gepirone and (+)WAY 100135 on territorial aggression in mice. Pharmacol Biochem Behav. 1998 Sep;61(1):1-8. PubMed PMID: 9715801. 4: Nakai K, Fujii T, Fujimoto K, Suzuki T, Kawashima K. Effect of WAY-100135 on the hippocampal acetylcholine release potentiated by 8-OH-DPAT, a serotonin1A receptor agonist, in normal and p-chlorophenylalanine-treated rats as measured by in vivo microdialysis. Neurosci Res. 1998 May;31(1):23-9. PubMed PMID: 9704975. 5: Boksa J, Klodzińska A, Charakchieva-Minol S, Chojnacka-Wójcik E, Mokrosz JL. Structure-activity relationship studies of CNS agents. Part 24: New analogs of N-tert.-butyl-3-[4-(2-methoxyphenyl)-1-piperazinyl]-2-phenylpropanamide (WAY-100135). Pharmazie. 1996 Feb;51(2):72-6. PubMed PMID: 8720802. 6: Rodgers RJ, Cole JC. Anxiolytic-like effect of (S)-WAY 100135, a 5-HT1A receptor antagonist, in the murine elevated plus-maze test. Eur J Pharmacol. 1994 Aug 22;261(3):321-5. PubMed PMID: 7813555. 7: Hartley JE, Fletcher A. The effects of WAY-100135 and 8-hydroxy-2-(di-n-propylamino)tetralin on feeding in the rat. Eur J Pharmacol. 1994 Feb 11;252(3):329-32. PubMed PMID: 8162954. 8: Löscher W, Hönack D. Effects of the novel 5-HT1A receptor antagonist, (+)-WAY 100135, on stereotyped behaviour induced by the NMDA receptor antagonist dizocilpine in rats. Eur J Pharmacol. 1993 Sep 21;242(1):99-104. PubMed PMID: 8223942. 9: Rhodes KF, Dover G, Lattimer N. The antagonist actions of WAY-100135 and its enantiomers on 5-HT1A receptor-mediated hyperpolarization of the rat isolated superior cervical ganglion. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):225-7. PubMed PMID: 8232599. 10: Chaouloff F, Aguerre S, Mormede P. GR 127935 and (+)-WAY 100135 do not affect TFMPP-induced inhibition of 5-HT synthesis in the midbrain and hippocampus of Wistar-Kyoto rats. Neuropharmacology. 1998 Sep;37(9):1159-67. PubMed PMID: 9833646. 11: Davidson C, Ho M, Price GW, Jones BJ, Stamford JA. (+)-WAY 100135, a partial agonist, at native and recombinant 5-HT1B/1D receptors. Br J Pharmacol. 1997 Jun;121(4):737-42. PubMed PMID: 9208142; PubMed Central PMCID: PMC1564750. 12: Fornal CA, Metzler CW, Gallegos RA, Veasey SC, McCreary AC, Jacobs BL. WAY-100635, a potent and selective 5-hydroxytryptamine1A antagonist, increases serotonergic neuronal activity in behaving cats: comparison with (S)-WAY-100135. J Pharmacol Exp Ther. 1996 Aug;278(2):752-62. PubMed PMID: 8768728. 13: Bell R, Mitchell PJ, Hobson H. Effects of the 5-HT1A antagonist (+)-WAY-100135 on murine social and agonistic behavior. Pharmacol Biochem Behav. 1996 May;54(1):159-67. PubMed PMID: 8728553. 14: Carli M, Luschi R, Samanin R. (S)-WAY 100135, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine. Eur J Pharmacol. 1995 Sep 5;283(1-3):133-9. PubMed PMID: 7498302. 15: Routledge C, Gurling J, Ashworth-Preece MA, Dourish CT. Differential effects of WAY-100135 on the decrease in 5-hydroxytryptamine release induced by buspirone and NAN-190. Eur J Pharmacol. 1995 Apr 4;276(3):281-4. PubMed PMID: 7601215. 16: Löscher W, Richter A. The novel selective and silent 5-HT1A receptor antagonist (+)-WAY-100135 aggravates dystonic movements in a mutant hamster model. Eur J Pharmacol. 1994 Apr 1;255(1-3):235-8. PubMed PMID: 8026548. 17: Escandon NA, Zimmermann DC, McCall RB. Characterization of the serotonin1A receptor antagonist activity of WAY-100135 and spiperone. J Pharmacol Exp Ther. 1994 Jan;268(1):441-7. PubMed PMID: 8301586. 18: Przegaliński E, Filip M, Budziszewska B, Chojnacka-Wójcik E. Antagonism of (+)WAY 100135 to behavioral, hypothermic and corticosterone effects induced by 8-OH-DPAT. Pol J Pharmacol. 1994 Jan-Apr;46(1-2):21-7. PubMed PMID: 7981767. 19: Cliffe IA, Brightwell CI, Fletcher A, Forster EA, Mansell HL, Reilly Y, Routledge C, White AC. (S)-N-tert-butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide [(S)-WAY-100135]: a selective antagonist at presynaptic and postsynaptic 5-HT1A receptors. J Med Chem. 1993 May 14;36(10):1509-10. PubMed PMID: 8496920.